Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia

A subset of chronic lymphocytic leukemia (CLL) carries mutations in ataxia telangiectasia mutated (ATM). Such ATM mutations may be particularly relevant in the setting of del11q, which invariably results in the deletion of one ATM allele. To improve our understanding of the frequency and type of ATM mutations that exist in CLL, we resequenced all ATM coding exons in 24 CLL with del11q using direct sequencing. We detected two missense mutations, resulting in an ATM mutation frequency of 8%; nonsense and frameshift mutations were not identified. Given the low ATM mutation frequency detected in this cohort, we proceeded with measurements of nonmutational ATM aberrations in CLL through analysis of the activation state of ATM in response to external irradiation. The phosphorylation state of ATM at Ser‐1981 was measured using quantitative immunoblotting in purified CLL cells isolated from 251 CLL patients; data were normalized to simultaneous measurements of total ATM protein and actin. Resulting p‐ATM/ATM and p‐ATM/actin ratios were subsequently analyzed for prognostic significance inclusive and exclusive of TP53 exons 2–10 mutations. From these analyses, conducted in a large prospectively enrolled CLL patient cohort, neither the p‐ATM/ATM nor the p‐ATM/actin ratios were found to be prognostic for short survival. These data in aggregate demonstrate a low frequency of ATM aberrations in an unselected CLL cohort and do not support a major prognostic role for ATM aberrations in CLL, thus motivating renewed research efforts aimed at understanding the pathobiology of 11q deletions in CLL. © 2012 Wiley Periodicals, Inc.

[1]  Y. Pekarsky,et al.  Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies. , 2012, Blood.

[2]  E. Giné,et al.  Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia , 2011, Nature Genetics.

[3]  K. Kinzler,et al.  Sequence analysis of 515 kinase genes in chronic lymphocytic leukemia , 2011, Leukemia.

[4]  A. Sivachenko,et al.  SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.

[5]  M. Kaminski,et al.  Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. , 2011, Blood.

[6]  N. Chiorazzi,et al.  Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. , 2011, Blood.

[7]  M. Kaminski,et al.  A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia , 2011, Clinical Cancer Research.

[8]  Y. Pekarsky,et al.  Tcl 1 interacts with Atm and enhances NF-kB activation in hematological malignancies , 2011 .

[9]  L. Ding,et al.  Aggressive Chronic Lymphocytic Leukemia with Elevated Genomic Complexity Is Associated with Multiple Gene Defects in the Response to DNA Double-Strand Breaks , 2010, Clinical Cancer Research.

[10]  A. Melnick,et al.  HELP (HpaII tiny fragment enrichment by ligation-mediated PCR) assay for DNA methylation profiling of primary normal and malignant B lymphocytes. , 2010, Methods in molecular biology.

[11]  M. Hallek,et al.  High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. , 2009, Blood.

[12]  T. Shanafelt,et al.  Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Quan Chen,et al.  An analytical pipeline for genomic representations used for cytosine methylation studies , 2008, Bioinform..

[14]  R. Siebert,et al.  Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Stankovic,et al.  Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. , 2005, Blood.

[16]  M. Kastan,et al.  DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation , 2003, Nature.

[17]  R. Houlston,et al.  ATM mutations are rare in familial chronic lymphocytic leukemia , 2002 .

[18]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[19]  H. Döhner,et al.  Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. , 1999, Blood.

[20]  T. Stankovic,et al.  Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia , 1999, The Lancet.

[21]  C. Croce,et al.  ATM mutations in B-cell chronic lymphocytic leukemia. , 1999, Cancer research.

[22]  H. Kantarjian,et al.  Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. , 1998, Cancer research.

[23]  C. Fegan,et al.  Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease. , 1995, Leukemia.

[24]  S. Knuutila,et al.  Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. , 1990, The New England journal of medicine.